Renal Toxicity - Absorption, Distribution, Metabolism, and Excretion (ADME) Toxicology Testing Market Report 2026

The renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market size has grown rapidly in recent years. It will grow from $1.52 billion in 2025 to $1.71 billion in 2026 at a compound annual growth rate (CAGR) of 12.7%. The growth in the historic period can be attributed to growth in preclinical drug safety testing, rise in nephrotoxicity related drug failures, expansion of CRO services, increased regulatory safety requirements, growth in in vitro assay adoption.

The renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increase in biologics and complex drugs, predictive toxicology model adoption, expansion of organ on chip platforms, precision medicine research growth, AI based safety analytics demand. Major trends in the forecast period include kidney organoid based toxicity assays, AI assisted nephrotoxicity prediction models, high throughput renal screening platforms, biomarker driven renal safety panels, microphysiological kidney on chip systems.

The increasing prevalence of kidney-related disorders is anticipated to drive the expansion of the renal toxicity-absorption, distribution, metabolism, and excretion (ADME) toxicology testing market in the future. Kidney-related disorders are medical conditions that impair the kidneys’ ability to filter blood and maintain body homeostasis. The incidence of these disorders is rising due to the growing rates of diabetes, which damages kidney blood vessels and compromises their filtration function. Renal toxicity ADME/toxicology testing aids in identifying and assessing potential kidney damage caused by drugs or chemicals, facilitating early intervention and the development of safer treatments. For example, in 2025, according to the American Cancer Society, a US-based professional organization, roughly 80,980 new cases of kidney (renal) cancer are projected to be diagnosed in the US, resulting in an estimated 14,510 deaths from the disease. Consequently, the increasing prevalence of kidney-related disorders is propelling the growth of the renal toxicity-ADME toxicology testing market.

Key companies operating in the renal toxicity-absorption, distribution, metabolism, and excretion (ADME) toxicology testing market are focusing on developing innovative solutions, such as low-drug-absorbing microfluidic chips, to improve predictive accuracy of kidney toxicity while reducing reliance on animal testing. A low-drug-absorbing microfluidic chip refers to a lab-on-a-chip device designed for renal toxicity testing that minimizes the unintended absorption of drugs by the chip material, ensuring more accurate simulation of kidney functions and reliable measurement of how drugs affect renal cells. For example, in September 2024, Emulate Inc., a US-based biotechnology company, launched the chip-R1 rigid chip to enhance kidney toxicity testing with more accurate and reliable results. It is built for accurate ADME and toxicology modeling in non-stretch organs like the liver and kidney, using low-drug-absorbing plastics and a thin, porous polycarbonate membrane to prevent compound loss and boost drug recovery for lipophilic compounds. Its advantages include high shear stress support (up to 2.3 dyn/cm²), preactivated surfaces for easy workflows, and better cellular crosstalk, while benefits encompass improved reproducibility, precise toxicity detection, and compatibility with existing organ-chip hardware to accelerate human-relevant preclinical testing.

In April 2025, CN Bio Innovations Ltd., a UK-based organ-on-a-chip technology company, formed a partnership with Pharmaron Beijing Co. Ltd. to implement its organ-on-a-chip platform for drug testing and development. This collaboration seeks to deploy PhysioMimix organ-on-a-chip technology across Pharmaron's global R&D facilities for toxicity assessment, including renal applications, ADME studies, disease modeling, and co-developing innovative human-relevant models to advance drug discovery while minimizing animal testing. Pharmaron Beijing Co. Ltd. is a China-based company providing renal toxicity ADME toxicology testing.

Major companies operating in the renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market are Thermo Fisher Scientific Inc., Eurofins Scientific SE, Agilent Technologies Inc., WuXi AppTec Co. Ltd., Charles River Laboratories International Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., Pharmaron Beijing Co. Ltd., Simulations Plus Inc., GVK Biosciences Pvt. Ltd., Promega Corporation, Syngene International Ltd., SAI Life Sciences Ltd., QPS Holdings LLC, Southern Research Institute, BioIVT LLC, TCG Lifesciences Pvt. Ltd., Frontage Laboratories Inc., Symeres, TSRL Inc., BOC Sciences LLC, Vivisciences Preclinical CRO.

Tariffs are influencing the renal toxicity ADME toxicology testing market by increasing the cost of imported laboratory instruments, assay kits, imaging systems, and microfluidic devices. Higher duties on specialized testing equipment and reagents are raising operational expenses for contract research organizations and advanced testing laboratories. Regions dependent on imported high end bioanalytical platforms and chip based systems are seeing budget pressure and slower lab expansion. In vitro and organ on chip technology segments are more exposed due to their hardware intensity. Smaller research labs are more sensitive to price increases linked to tariffs. At the same time, tariffs are encouraging local production of lab consumables and analytical tools. This is gradually strengthening domestic laboratory supply ecosystems.

The renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market research report is one of a series of new reports that provides renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market statistics, including renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing industry global market size, regional shares, competitors with a renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market share, detailed renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing industry. This renal toxicity - absorption, distribution, metabolism, and excretion (adme) toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Renal toxicity-absorption, distribution, metabolism, and excretion (ADME) toxicology testing is a specialized safety and pharmacokinetic evaluation method that examines the potential kidney-related risks of pharmaceutical and biotechnology compounds by studying their absorption, distribution, metabolism, and elimination. This testing combines laboratory, animal, and computational approaches to assess drug interactions with renal tissues and predict nephrotoxic effects during development stages.

The primary types of renal toxicity-absorption, distribution, metabolism, and excretion (ADME) toxicology testing include in vitro renal toxicity testing, in vivo renal toxicity testing, and in silico renal toxicity modeling. In vitro renal toxicity testing refers to laboratory-based approaches used to assess the potential toxic effects of compounds on kidney cells or tissues. These tests are performed using methods such as biochemical and enzymatic assays, cell-based renal assays, biomarker-based toxicity analysis, histopathology and imaging, and pharmacokinetic and drug metabolism studies. They are applied across drug development stages including discovery and lead optimization, preclinical development, clinical development, and post-marketing safety studies. They utilize technologies including high-throughput screening platforms, organ-on-chip and microfluidic systems, omics-based toxicology platforms, artificial intelligence and predictive modeling tools, and digital pathology and imaging systems, and are used by end users including pharmaceutical and biotechnology companies, contract research organizations (CROs), academic and research institutes, and regulatory laboratories.

The renal toxicity-absorption, distribution, metabolism, and excretion (ADME) toxicology testing market includes revenues earned by entities through laboratory-based testing services, preclinical and clinical evaluation, data analysis, and regulatory support. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.